Predictors of 5-year arrhythmia recurrence after treatment of typical atrial flutter in patients with coronary artery disease

Abstract

BACKGROUND: There is no consensus on the predictors of arrhythmia recurrence following treatment for typical atrial flutter.

AIM: The study aimed to identify the factors associated with arrhythmia recurrence in patients with coronary artery disease and typical atrial flutter after cardioversion.

METHODS: The study included 165 patients who underwent different treatment modalities, including pharmacological cardioversion with amiodarone (61 patients), electrical cardioversion (20 patients), transesophageal atrial pacing (48 patients), and radiofrequency ablation (36 patients). Patients underwent a 5-year follow-up at intervals of 6, 12, 24, 36, 48, and 60 months.

The predictors of arrhythmia recurrence were determined by analyzing correlation coefficients using Pearson’s (r) and Spearman’s (R) tests, depending on data distribution, followed by multiple regression analysis and receiver operating characteristic (ROC) analysis, including area under the curve (AUC) calculation. The statistical analysis assessed the influence of sex, age, height, weight, body mass index, body surface area, smoking status, arrhythmia characteristics, and comorbidities (atrial flutter type, arrhythmia duration, time since last recurrence, history of atrial fibrillation, symptom severity using the EHRA scale, CHA₂DS₂-VASc and HAS-BLED scores, presence of silent myocardial ischemia and ventricular arrhythmias based on 24-hour Holter ECG monitoring, lipid profile, functional class of angina and heart failure, prior percutaneous coronary intervention with stenting, and history of coronary artery bypass grafting). Structural and functional parameters of the atria and left ventricle were assessed using transthoracic echocardiography. Statistical significance was set at p < 0.05.

RESULTS: The success rates in restoring sinus rhythm were as follows: 54.1% with pharmacological cardioversion, 87.5% with transesophageal atrial pacing combined with amiodarone, 95.0% with electrical cardioversion, and 100% with radiofrequency ablation with cryoisolation of the pulmonary vein ostia. Arrhythmia recurrence was identified in 62.42% of patients. Significant predictors of atrial flutter recurrence included obesity grade ≥2 (AUC = 0.655; p = 0.0117), regular-type atrial flutter (AUC = 0.736; p < 0.0001), and a history of coronary angioplasty with stenting (AUC = 0.687; p < 0.0001). Following conservative cardioversion, a history of atrial fibrillation was the primary predictor of atrial fibrillation recurrence. After ablation, recurrence was predicted by age >62 years (AUC = 0.703; p = 0.0211) and left ventricular diastolic diameter >5.3 cm (AUC = 0.703; p = 0.0305). Predictors of atrial flutter-to-fibrillation recurrence included a history of atrial fibrillation (AUC = 0.702; p = 0.0193), left atrial dilation (AUC = 0.714; p = 0.0439), and left ventricular hypertrophy (AUC = 0.703; p = 0.0121).

CONCLUSION: The five-year recurrence of atrial flutter is associated with the severity of underlying cardiovascular pathology, whereas atrial fibrillation recurrence is linked to a history of atrial fibrillation, patient age, and structural remodeling of the left heart chambers.

Keywords

typical atrial flutter / conservative treatment / surgical treatment / predictors of arrhythmia recurrence

References

[1] Katritsis DG, Morady F. Clinical сardiac electrophysiology: a practical guide. 1st ed. Philadelphia: Elsevier; 2021. 392 p.

[2] Katritsis D.G., Morady F. Clinical сardiac electrophysiology: a practical guide. 1st ed. Philadelphia: Elsevier, 2021. 392 p.

[3] Ardashev AV. Clinical arrhythmology. 2nd ed. Vol. 4. Moscow: ID MEDPRAKTIKA-M; 2021. 454 p. (In Russ.)

[4] Ардашев А.В. Клиническая аритмология. Изд. 2-е. Т. 4. М.: ИД «МЕДПРАКТИКА-М», 2021. 454 с.

[5] Libby P, Bonow RO, Mann DL, et al. Braunwald’s heart disease: a textbook of cardiovascular medicine. 12th ed. Philadelphia: Elsevier; 2021. 2034 p.

[6] Libby P., Bonow R.O., Mann D.L., et al. Braunwald’s heart disease: a textbook of cardiovascular medicine. 12th ed. Philadelphia: Elsevier, 2021. 2034 p.

[7] Rahman F, Wang N, Yin X, et al. Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm. 2016;13(1):233–240. doi: 10.1016/j.hrthm.2015.07.031

[8] Rahman F., Wang N., Yin X., et al. Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study // Heart Rhythm. 2016. Vol. 13, N. 1. P. 233–240. doi: 10.1016/j.hrthm.2015.07.031

[9] Potapova KV, Nosov VР, Koroleva LYu, Amineva NV. Increasing eff ectiveness method of conservative treatment of typical atrial flutter. Clinical Medicine (Russian Journal). 2020;98(5):334–340. doi: 10.30629/0023-2149-2020-98-5-334-340

[10] Потапова К.В., Носов В.П., Королева Л.Ю., Аминева Н.В. Способ повышения эффективности консервативного лечения типичного трепетания предсердий // Клиническая медицина. 2020. Т. 98, № 5. С. 334–340. doi: 10.30629/0023-2149-2020-98-5-334-340

[11] Kushakovskiy MS, Grishkin YuN. Cardiac arrhythmias. Heart rhythm disorders and conduction disorders. Causes, mechanisms, electrocardiographic and electrophysiological diagnostics, clinical picture, treatment: A guide for doctors. 4th ed. Saint Petersburg: Foliant; 2020. 720 p. (In Russ.)

[12] Кушаковский М.С., Гришкин Ю.Н. Аритмии сердца. Расстройства сердечного ритма и нарушения проводимости. Причины, механизмы, электрокардиографическая и электрофизиологическая диагностика, клиника, лечение: Руководство для врачей. 4-е изд., испр. и доп. СПб: Фолиант, 2020. 720 с.

[13] Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655–720. doi: 10.1093/eurheartj/ehz467

[14] Brugada J., Katritsis D.G., Arbelo E., et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC) // Eur Heart J. 2020. Vol. 41, N. 5. P. 655–720. doi: 10.1093/eurheartj/ehz467

[15] Bunin YuA, Miklishanskaya SV, Zolozova EA, Chigineva VV. Atrial tachyarrhythmias and atrial flutter: The basics of diagnostics and modern opportunities of therapy. Ratsional'naya Farmakoterapiya v Kardiologii. 2019;15(1):115–124. (In Russ.) doi: 10.20996/1819-6446-2019-15-1-115-124

[16] Бунин Ю.А., Миклишанская С.В., Золозова Е.А., Чигинева В.В. Предсердные тахикардии и трепетание предсердий: основы диагностики и современные возможности терапии // Рациональная Фармакотерапия в Кардиологии. 2019. Т. 15, № 1. С. 115–124. doi: 10.20996/1819-6446-2019-15-1-115-124

[17] Novikov PS, Shlevkov NB, Pevzner AV, et al. Incidence and risk factors of atrial fibrillation after radiofrequency catheter ablation of cavo-tricuspid isthmus in patients with isolated typical atrial flutter. Vestnik aritmologii. 2016;(84):5–11. (In Russ.) EDN: XGRFDF

[18] Новиков П.С., Шлевков Н.Б., Певзнер А.В., и др. Частота возникновения и факторы риска развития фибрилляции предсердий после радиочастотной катетерной аблации каватрикуспидального истмуса у больных с «изолированным» типичным трепетанием предсердий // Вестник аритмологии. 2016. № 84. С. 5–11. EDN: XGRFDF

[19] Steklov VI, Sergoventsev AA, Rzaev FG, et al. Predictors of atrial fibrillation in patients with atrial flutter after radiofrequency ablation of the lower isthmus. Vestnik aritmologii. 2017;(87):23–28. (In Russ.) EDN: YPHPBH

[20] Стеклов В.И., Серговенцев А.А., Рзаев Ф.Г., и др. Предикторы фибрилляции предсердий у пациентов с трепетанием предсердий после радиочастотной аблации нижнего перешейка // Вестник аритмологии. 2017. № 87. С. 23–28. EDN: YPHPBH

[21] De Bortoli A, Shi L-B, Ohm O-J, et al. Incidence and clinical predictors of subsequent atrial fibrillation requiring additional ablation after cavotricuspid isthmus ablation for typical atrial flutter. Scand Cardiovasc J. 2017;51(3):123–128. doi: 10.1080/14017431.2017.1304570

[22] De Bortoli A., Shi L.-B., Ohm O.-J., et al. Incidence and clinical predictors of subsequent atrial fibrillation requiring additional ablation after cavotricuspid isthmus ablation for typical atrial flutter // Scand Cardiovasc J. 2017. Vol. 51, N. 3. P. 123–128. doi: 10.1080/14017431.2017.1304570

[23] Warchoł I, Bińkowski BJ, Kucejko T, et al. A retrospective study of atrial fibrillation following cavotricuspid isthmus ablation for atrial flutter. Med Sci Monit. 2019;5(25):3316–3320. doi: 10.12659/MSM.912918

[24] Warchoł I., Bińkowski B.J., Kucejko T., et al. A retrospective study of atrial fibrillation following cavotricuspid isthmus ablation for atrial flutter // Med Sci Monit. 2019. Vol. 5, N. 25. P. 3316–3320. doi: 10.12659/MSM.912918

[25] Dechering D, Gonska B-D, Brachmann J. Efficacy and complications of cavo-tricuspid isthmus-dependent atrial flutter ablation in patients with and without structural heart disease: results from the German Ablation Registry. J Interv Card Electrophysiol. 2021;61(1):55–62. doi: 10.1007/s10840-020-00769-z

[26] Dechering D.G., Gonska B.D., Brachmann J., et al. Efficacy and complications of cavo-tricuspid isthmus-dependent atrial flutter ablation in patients with and without structural heart disease: results from the German Ablation Registry // J Interv Card Electrophysiol. 2021. Vol. 61, N. 1. P. 55–62. doi: 10.1007/s10840-020-00769-z

[27] Foo FSh, Kerr A, Gabriel R, et al. Early direct current cardioversion or ablation for atrial fibrillation or atrial flutter and acute decompensated heart failure. N Z Med J. 2019;132(1496):39–46.

[28] Foo F.S., Kerr A., Gabriel R., et al. Early direct current cardioversion or ablation for atrial fibrillation or atrial flutter and acute decompensated heart failure // N Z Med J. 2019. Vol. 132, N. 1496. P. 39–46.

[29] Potapova KV, Nosov VP, Koroleva LYu. Sinus rhythm restoration and preservation predictors during conservative and surgical treatment of typical atrial flutter in patients with chronic forms of coronary heart disease. Medical almanac. 2024;80(3):22–31. EDN: TRLYNR

[30] Потапова К.В., Носов А.П., Королева Л.Ю. Предикторы восстановления и сохранения синусового ритма при консервативном и хирургическом лечении типичного трепетания предсердий у больных хроническими формами ишемической болезни сердца // Медицинский альманах. 2024. Т. 80, № 3. С. 22–31. EDN: TRLYNR

[31] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612

[32] Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC // Eur Heart J. 2021. Vol. 42, N. 5. P. 373–498. doi: 10.1093/eurheartj/ehaa612

[33] Arakelyan MG, Bokeriya LA, Vasil'eva EYu, et al. 2020 Clinical guidelines for atrial fibrillation and flutter. Russian J Cardiol. 2021;26(7):4594. (In Russ.) doi: 10.15829/1560-4071-2021-4594

[34] Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020 // Российский кардиологический журнал. 2021. Т. 26, № 7. С. 4594. doi: 10.15829/1560-4071-2021-4594

[35] José A, Joglar JA, Chung MK, et al 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1–e156. doi: 10.1161/CIR.0000000000001193

[36] José A., Joglar J.A., Mina K., et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines // Circulation. 2024. Vol. 149, N. 1. P. e1–e156. doi: 10.1161/CIR.0000000000001193

[37] Olesin AI, Smolin ZYu, Konovalova OA, Shabrov AV. Efficacy of transesophageal pacing for correction of newly diagnosed atrial fibrillation of type I in patients with coronary heart disease. Terapevticheskii arkhiv. 2009;81(9):37–41. (In Russ.) EDN: KZRAJD

[38] Олесин А.И., Смолин З.Ю., Коновалова О.А., Шабров А.В. Оценка эффективности чреспищеводной электрокардиостимуляции для купирования впервые выявленного трепетания предсердий I типа у больных ишемической болезнью сердца // Терапевтический архив. 2009. Т. 81, № 9. С. 37–41. EDN: KZRAJD

[39] Sulimov VA, Dubrovskiy IA, Kanorskiy SG. Transesophageal electrical stimulation of the heart. 2 nd ed. Moscow: GEOTAR-Media; 2015. 216 p. (In Russ.)

[40] Сулимов В.А., Дубровский И.А., Канорский С.Г. Чреспищеводная электрическая стимуляция сердца. Изд. 2-е. М.: ГЭОТАР-Медиа, 2015. 216 с.

[41] Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–354. doi: 10.1111/j.1751-7176.2008.07572.x

[42] Morisky D.E., Ang A., Krousel-Wood M., Ward H.J. Predictive validity of a medication adherence measure in an outpatient setting // J Clin Hypertens. 2008. Vol. 10, N. 5. P. 348–354. doi: 10.1111/j.1751-7176.2008.07572.x

[43] Da Costa А, Thévenin J, Roche F, et al. Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation. 2006;114(16):1676–1681. doi: 10.1161/CIRCULATIONAHA.106.638395

[44] Da Costa А., Thévenin J., Roche F., et al. Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter // Circulation. 2006. Vol. 114, N. 16. P. 1676–1681. doi: 10.1161/CIRCULATIONAHA.106.638395

[45] Toner L, Proimos H, Scully T, et al. Late recurrence of atrial fibrillation and flutter in patients referred for elective electrical cardioversion. Kardiologiia. 2023;63(1):54–59. doi: 10.18087/cardio.2023.1.n2145

[46] Toner L., Proimos H., Scully T., et al. Late recurrence of atrial fibrillation and flutter in patients referred for elective electrical cardioversion // Kardiologiia. 2023. Vol. 63, N. 1. P. 54–59. doi: 10.18087/cardio.2023.1.n2145

[47] Chen K, Bai R, Deng W, et al. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. Heart Rhythm. 2015;12(7):1483–1489. doi: 10.1016/j.hrthm.2015.04.008

[48] Chen K., Bai R., Deng W., et al. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter // Heart Rhythm. 2015. Vol. 12, N. 7. P. 1483–1489. doi: 10.1016/j.hrthm.2015.04.008

RIGHTS & PERMISSIONS

Eco-Vector